Eradivir’s founder, Dr. Philip S. Low, has successfully developed multiple FDA-approved targeted small molecules. These therapies all function by attaching various payloads to ligands, which bind with high specificity to diseased cells. Examples of approved molecules include a radiotherapy drug for prostate cancer and an intraoperative imaging agent for lung and ovarian cancers. Several others are currently in clinical trials (e.g., treatments for cancer, malaria, and sickle cell anemia). Eradivir was founded in March 2020 to advance a promising application of this platform in combating multiple disease states, initially focusing on influenza and other respiratory infections.
Total raised: $10.25M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.09.2024 | Series A | $10.25M | - |
Mentions in press and media 4
| Date | Title | Description |
| 27.09.2024 | Eradivir Secures $10.25 Million to Battle Influenza with Innovative Therapy | In the world of biotechnology, funding is the lifeblood that fuels innovation. Recently, Eradivir, a preclinical biotech company based in West Lafayette, Indiana, secured $10.25 million in a Series A funding round. This financial boost is s... |
| 26.09.2024 | Eradivir Closes $10.25M Series A Funding | Eradivir, a West Lafayette, IN-based preclinical biotech company that develops antiviral therapeutics, raised $10.25M in Series A funding. Funding was raised with investments from Philip Low, board members and other members of the company. ... |
| 25.09.2024 | Biotech company Eradivir closes $10.25M Series A funding round to complete Phase 2a study of influenza therapeutic | WEST LAFAYETTE, Ind., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The funding will be used to conduct a Phase 2a cha... |
| - | Eradivir | “Eradivir” |